Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.
about
Heat shock proteins 70 and 60 share common receptors which are expressed on human monocyte-derived but not epidermal dendritic cellsTherapeutic cancer vaccines: using unique antigensSpatiotemporal Regulation of Hsp90-Ligand Complex Leads to Immune ActivationHeat Shock Protein-Peptide and HSP-Based Immunotherapies for the Treatment of CancerEndoplasmic Reticulum Stress Interacts With Inflammation in Human DiseasesLocal tumour hyperthermia as immunotherapy for metastatic cancer.Therapeutic cancer vaccines: past, present, and futureClients and Oncogenic Roles of Molecular Chaperone gp96/grp94Identification of chaperones as essential components of the tumor rejection moieties of cancersIdentification of the peptide-binding site in the heat shock chaperone/tumor rejection antigen gp96 (Grp94).Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.Identification of peptide mimotopes of gp96 using single-chain antibody library.The allure and peril of hematopoietic stem cell transplantation: overcoming immune challenges to improve success.Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts.Radiation therapy induces circulating serum Hsp72 in patients with prostate cancerEnhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EBI-1-ligand chemokine and stromal cell-derived factor-1alpha chemokine genes.An overview of cancer immunotherapy.Heat shock proteins and cancer immunotherapy.A heat shock protein 70-based vaccine with enhanced immunogenicity for clinical use.Covalent crosslinking of tumor antigens stimulates an antitumor immune response.Heat shock proteins: the fountainhead of innate and adaptive immune responses.The heat shock protein gp96: a receptor-targeted cross-priming carrier and activator of dendritic cells.High efficiency CD91- and LOX-1-mediated re-presentation of gp96-chaperoned peptides by MHC II molecules.Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infectionHSPPC-96: a personalised cancer vaccine.Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses.Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccinesHeat-shock protein-based vaccines for cancer and infectious disease.Monoclonal antibody 16D10 to the C-terminal domain of the feto-acinar pancreatic protein binds to membrane of human pancreatic tumoral SOJ-6 cells and inhibits the growth of tumor xenografts.Mechanisms of Translocation of ER Chaperones to the Cell Surface and Immunomodulatory Roles in Cancer and Autoimmunity.Prospects for immunotherapy of malignant disease.The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7.HSP70 peptidembearing and peptide-negative preparations act as chaperokines.Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70The inducible Hsp70 as a marker of tumor immunogenicityFacets of heat shock protein 70 show immunotherapeutic potential.Role of heat shock proteins in diseases and their therapeutic potential.CD91-dependent programming of T-helper cell responses following heat shock protein immunization.
P2860
Q24292217-0490252B-C8BD-4C88-A1A4-A9CF9159FB2FQ24563772-5FE37786-2117-46F2-86E3-B2DED0BEF135Q26744078-FAAF594F-6286-4BE1-9853-60CC1A1F3D03Q26747392-7CBEF84D-F445-4563-9F07-68B9C6E0F105Q26800781-2F3FE806-1E43-405F-B416-0FB09A55F636Q26823968-429E04F5-6AA9-485E-8679-7C3314CAFC65Q26863283-9DF93854-C4E6-443A-9CC4-4586F6AC4A69Q28075479-48B45C28-DA38-4492-91C6-5D556B68BBB7Q28728195-90045F82-B973-4433-AD8C-3E328808959BQ30840326-848AF3CF-0758-4303-9523-AB20381F8AE4Q33585305-DDD59EC7-F6E6-42D0-BEBA-29E93D83DBFDQ33720789-E87FA8F3-3670-4CA8-9068-0640BCAC0F4BQ33724352-2FEC7BBF-BFF8-486B-B4FC-CA756526C480Q33756673-9A8BC5FB-C5F1-464B-A2FD-A28102B4B508Q33879089-C8A18EED-0E92-4D96-8DB7-D29E1BE62815Q33905697-16A61FF0-80CB-4E09-947C-457ED0747DF7Q33939602-A9AF63D6-D245-4570-9D3E-B8CF145FBD0BQ33940388-AB009083-95AA-4D41-B737-8DE9B53E1FF5Q33943138-C6CDF443-7512-46A3-9630-6C256E083E4FQ34024513-F3C1B0FE-9740-4D07-8170-4CF1E96939F7Q34138809-DE64284C-C46D-4E51-81AF-8CB53113D9A4Q34145113-285EF72F-2860-43BC-995B-081B4550CCF8Q34145128-8BA3270D-CE1B-428F-A606-A253E312FD83Q34240327-53CAFE49-A9F1-4905-AFAB-F801AEFCBFFFQ34326744-F49A93DC-C8DE-47C3-941A-5F0D45FF8D9DQ34452027-82E226E1-BD44-47C2-9836-92A7D0C82962Q34555318-99865C68-2346-4175-84B1-35D3EB2C92B4Q34627942-0973B109-6B5E-42D6-B7CB-D450FB75A6E1Q34768299-0108570E-1813-4C45-AF1C-980976EEEE93Q34928685-DB2C8CE7-35F3-4F62-A119-1F3307166EF8Q35025948-B5531BC2-EB40-473D-9DF2-71F049448425Q35041705-EFE22336-E7F4-4EAE-A040-2E9A69C359F8Q35049933-9258DE74-0C65-41B4-9A5D-016DAA2180C8Q35083890-6BCC49C6-D3F1-4C24-BACA-314F80C2D199Q35083995-356FD823-CB77-4D82-BAE4-A1220A9B628BQ35113737-4804B013-94CA-42EE-8AD2-924F2CA41919Q35129813-D520BAD4-9503-47BB-A41A-6BA92D346F83Q35206769-331808D8-8B77-46D7-A8F9-C3E010C4CACBQ35533014-46E9E11E-05EB-4125-A692-385EC7ADF70BQ35973873-21142F3A-1374-48D7-B445-6E444A48645B
P2860
Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@ast
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@en
type
label
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@ast
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@en
prefLabel
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@ast
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@en
P2093
P2860
P356
P1476
Cellular requirements for tumo ...... 6 primes CD8+ T cells in vivo.
@en
P2093
P K Srivastava
P2860
P304
P356
10.1073/PNAS.91.8.3077
P407
P577
1994-04-01T00:00:00Z